Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$27,000.00
Revealing and Targeting the Molecular and Cellular Roots of Seizure Initiation
FY 2024-25
Summary
Epilepsy is a devastating neurological disease characterized by recurrent seizures. Of the 50 million affected individuals worldwide, nearly 1 in 3 suffer from epilepsy that is resistant to drug treatments. The reason for drug resistance is multifactorial: current drugs struggle to treat the root cause of epilepsy due to a lack of understanding of the specific brain cell types and molecules involved in seizure generation, and the development of new epilepsy drugs is complicated by a generally inefficient and expensive drug discovery pipeline. This work aims to overcome these challenges by identifying seizure-initiating cell types while also utilizing a computer-aided workflow to accelerate the development of new epilepsy drugs. In collaboration with neurosurgeons and neuropathologists at Vancouver General Hospital, our lab will culture brain tissue obtained from surgeries of consenting epilepsy patients. State-of-the-art imaging and sequencing techniques will pinpoint the cell types and their unique molecules involved in seizure generation. These cell types will be targeted using drug candidates identified using structural bioinformatics techniques. The efficacy of these drugs in treating seizures will be assessed in human brain tissue as well as a mouse model of epilepsy. Overall, this work will deepen our anatomical and functional understanding of seizure generation in the brain while producing promising new drug candidates for epilepsy treatment, especially in cases of drug-resistant epilepsy.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530174
Name
Dang An T
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Revealing and Targeting the Molecular and Cellular Roots of Seizure Initiation
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Brain Tissue Culture; Cell Types; Drug Discovery; Drug Resistance; Epilepsy; Neuroscience; Seizures; Structural Bioinformatics; Transcriptomics
Abstract
Epilepsy is a devastating neurological disease characterized by recurrent seizures. Of the 50 million affected individuals worldwide, nearly 1 in 3 suffer from epilepsy that is resistant to drug treatments. The reason for drug resistance is multifactorial: current drugs struggle to treat the root cause of epilepsy due to a lack of understanding of the specific brain cell types and molecules involved in seizure generation, and the development of new epilepsy drugs is complicated by a generally inefficient and expensive drug discovery pipeline. This work aims to overcome these challenges by identifying seizure-initiating cell types while also utilizing a computer-aided workflow to accelerate the development of new epilepsy drugs. In collaboration with neurosurgeons and neuropathologists at Vancouver General Hospital, our lab will culture brain tissue obtained from surgeries of consenting epilepsy patients. State-of-the-art imaging and sequencing techniques will pinpoint the cell types and their unique molecules involved in seizure generation. These cell types will be targeted using drug candidates identified using structural bioinformatics techniques. The efficacy of these drugs in treating seizures will be assessed in human brain tissue as well as a mouse model of epilepsy. Overall, this work will deepen our anatomical and functional understanding of seizure generation in the brain while producing promising new drug candidates for epilepsy treatment, especially in cases of drug-resistant epilepsy.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dang, An T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~